Jun 30, 2023

Avantor Q2 2023 Earnings Report

Avantor's financial performance reflected a challenging biopharma market, with strategic actions taken to offset headwinds and invest in long-term growth.

Key Takeaways

Avantor reported a decrease in net sales by 8.7% to $1.74 billion, with a core organic decline of 6.5%. Net income was ($7.3) million, while adjusted EBITDA reached $343.0 million. The company's diluted GAAP EPS was ($0.01), and adjusted EPS was $0.28. Operating cash flow was $168.2 million, and free cash flow was $138.1 million.

Net sales decreased by 8.7% to $1.74 billion, with a core organic decline of 6.5%.

Adjusted EBITDA was $343.0 million with a margin of 19.7%.

Diluted GAAP EPS was ($0.01), and adjusted EPS was $0.28.

Operating cash flow was $168.2 million, and free cash flow was $138.1 million.

Total Revenue
$1.74B
Previous year: $1.91B
-8.7%
EPS
$0.28
Previous year: $0.37
-24.3%
Adjusted EBITDA
$343M
Previous year: $404M
-15.1%
Gross Profit
$590M
Previous year: $648M
-8.9%
Cash and Equivalents
$236M
Previous year: $238M
-0.5%
Free Cash Flow
$138M
Previous year: $191M
-27.8%
Total Assets
$13.1B
Previous year: $13.4B
-2.7%

Avantor

Avantor

Avantor Revenue by Geographic Location

Forward Guidance

No forward guidance was provided in the press release.

Revenue & Expenses

Visualization of income flow from segment revenue to net income